Buradasınız

Anasayfa » Content

Ratlarda Transvers Rektus Abdominis Kas Deri Flep Modelinde Nebivololün Perfüzyona Etkileri

Effect of Nebivolol on Rat TRAM Flap Viability

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Breast reconstruction is an essential part of the breast cancer threapy. The transverse rectus abdominis musculocutaneous (TRAM) flap has been widely used for reconstruction of the breast. Partial loss of the flap is still a major problem. The defficiency of flap perfusion may cause partial necrosis of the flap. Periferic vasodilatation may increases flap viability. The aim of this study is evaluation of affect of nebivolol on rat TRAM flap perfusion. Nebivolol is a selective β1 adrenergic receptor antagonist that causes a direct vasodilator effect attributed to the action on vascular nitric oxide (NO). In this study 30 male spraque–dawley rats were used. A pedicled TRAM flap based upon the the right inferior epigastric artery was elevated and reapproximated. Animals were randomly assigned to 5 treatment groups (n:6). Group 1 received no nebivolol. Groups 2 through 5 were administered 100 mg/kg nebivolol orally 24 hours preoperatif; in addition groups 2 to 4 received orally postoperatif for 7 days. Group 3 also received intraoperatively; groups 4 and 5 were given nebivolol orally for 7 days before the 24 hours preoperatif treatment. Seven days after surgery skin paddles were photographed and assessed for viability. In seventh day blood lactate levels were measured. Statically significant differences were found in all experimental groups relative to the controls. Group 4 displayed the greatest improvement in flap viability, significantly better than other nebivolol groups. This study indicates that nebivolol may provide a useful pharmacologic tool for reducing iscemia-reletad necrosis in TRAM flaps.
Bookmark/Search this post with
Abstract (Original Language): 
Meme rekonstruksiyonu; meme kanserinin cerrahi tedavisinin bir parçası olarak düşünülmektedir. Rekonstrüksiyon seçenekleri arasında bulunan transvers rektus abdominis kas deri flebinin (TRAM) belirli beslenme zonlarındaki perfüzyon yetersizlikleri, cerrahi sonrası görülen komplikasyonların artmasına neden olmaktadır. Periferik vazodilatasyonla kanlanma artırıldığında, flep viabilitesi artmakta ve komplikasyon riski azaltılabilmektedir. Nebivolol, üçüncü kuşak beta-adrenoreseptor blokeri olup nitrik oksit aracılığıyla periferik vazodilatasyon yapmaktadır. Çalışmada otuz adet, 250-300 gr ağırlığında Spraque- Dawley rat, beş deney grubuna ayrıldı. Tüm gruplarda TRAM flep kaldırıldı. Kontrol grubu kabul edilen birinci gruba ilaç uygulanmadı. İkinci gruba cerrahi işlemden 24 saat önce 100 mg/kg nebivolol (Vazoksen, Abdi Ibrahim) oral gavaj yöntemi ile başlandı ve postoperatif 7 gün uygulamaya devam edildi. Üçüncü gruba cerrahi işlemden 24 saat önce 100 mg/kg nebivolol, verildi. Peroperatif dönemde ve postoperatif 7 gün devam edildi. Dördüncü gruba cerrahi işlemden 7 gün önce 100 mg/kg nebivolol başlandı ve postoperatif dönemde 7 gün devam edildi. Beşinci gruba cerrahi işlemden 7 gün önce 100 mg/kg nebivolol kullanıldı. Peroperatif veya postoperatif dönemde ilaç kullanılmadı. Yedinci gün, tüm ratlarda kan laktat düzeyi ölçüldü ve fleplerin fotoğrafları çekilerek, nekroz alanlarının yüzdeleri belirlendi. Kan laktat değerlerinin, istatistiksel olarak tüm gruplarda kontrol grubuna (grup I) göre belirgin farklılık gösterdiği bulundu. En anlamlı fark kontrol grubu ile (grup 4) arasında tespit edildi. Fleplerin nekroz oranlarının değerlendirmelerinde, istatistiksel olarak grup 1’e göre diğer tüm gruplarda anlamlı fark mevcuttu (p<0.005). Kontrol grubuna göre, preoperatif ve postoperatif dönemde nebivolol’un kullanıldığı grup 4’te belirgin fark mevcuttu. Bu çalışma, nebivololün, TRAM flepde perfüzyonu artırarak iskemiye bağlı nekrozun azaltılmasında faydalı bir ilaç olduğunu düşündürmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-ratlarda-transvers-rektus-abdominis-kas-deri-flep-modelinde-nebivololun-perfuzyona-etkileri.pdf
  • 1
14-18
  • Turkish

REFERENCES

References: 

1- Chargari C, Kirova YM, Forquet A. Breast reconstruction after
breast-cancer surgery. N Engl J Med 2009;360:420-1.
2- Kroll SS, Baldwin B. A comparison of outcomes using three
different methods of breast reconstruction. Plast Reconstr
Surg 1992;90:455-62.
3- Munzel T, Gori T. Nebivolol the somewhat-different betaadrenergic receptor blocker. J Am Coll Cardioll 2009;54:1491-
9.
4- Baldwin CM, Keam SJ, Nebivolol: in the treatment of
hypertension in the US. Am J Cardiovasc Drugs 2009;9:253-
60.
5- Mason RP, Giles TD, Sowers JR. Evolving mechanisms of
action of beta-blockers: focus on nebivolol. J Cardiovasc
Pharmacol 2009;54:123-8.
6- Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther
Adv Cardiovasc Dis 2009;3:317-27.
7- Tzemos N, Lim O, Mac Donald M. Nebivolol reverses endothelial
dysfunction in essential hypertension a randomized, doubleblind, crossover study. Circulation 2001;104:511–14.
8- Zhang F, Lineawever WC, Kao S. Microvascular transfer of
the rectus abdominis muscle and myocutaneous flap in rats.
Microsurgery 1993;14:420.
9- Dunn RM, Huff W, Mancoll J. The rat rectus abdominis
myocutaneous flap: a true myocutaneous flap model. Ann Plast
Surg 1993;31:352.
10- Bayramiçli M. Deneysel Mikrocerrahi. İstanbul 2005:515-9.
11. Hartrampf C, Scheflan M, Black P. Breast reconstruction with
a transverse abdominal island flap. Plast Rec Surg 1982;69:
216-25.
12- Hartrampf CR Jr. Breast reconstruction with living tissue. New
York: Raven Pres, 1990.
13- Doncatto LF, da Silva JB, da Silva VD, et al. Cutaneous
Viability in a Rat Pedicled TRAM Flap Model. Plast Reconstr
Surg 2007; 119:1425-30.
14- Erdmann D, Sundin BM, Moquin KJ, et al. Delay in unipedicled
TRAM flap reconstruction of the breast: A review of 76
consecutive cases. Plast. Reconstr. Surg 2002;110:762-7.
15- Scheufler O, Exner K, Andresen R. Investigation of TRAM
flap oxygenation and perfusion by near-infrared reflection
spectroscopy and color-coded duplex sonography. Plast
Reconstr Surg 2004;113:141-9.
16- Shalom A, Friedman T, Westreich M. Effect of aspirin and
heparin on random skin flap survival in rats. Dermatol Surg 2008;
34:785-90.
17- Torkvist L, Lofberg R, Raud J, et al. Heparin protects against
skin flap necrosis: relationship to neutrophil recruitment and
anti-coagulant activity. Inflamm Res 2004;53:1-3.
18- Akan M, Cakir B, Misirlioglu A, et al. Effects of clopidogrel and
high dose aspirin on survival of skin flaps in rats. Scand J Plast
Reconstr Surg Hand Surg 2005;39:7-10.
19- Krapohl BD, Siemionow M, Zins JE. Tissue-plasminogen
activator restores muscle flap perfusion in the rat. J Hand Surg
Am 1999;24:1036-44.
20- Willemart G, Knight KR, Morrison WA. Dexamethasone
treatment prior to reperfusion improves the survival of skin
flaps subjected to secondary venous ischaemia. Br J Plast
Surg 1998;51:624-8.
21- Jallalı N. Dextrans in microsurgery: a review. Microsurg: 2003;
23:78–80.
22- Tyner TR, Tong W, Donovan K, et al. Dichloroacetate Reduces
Tissue Necrosis in a Rat Transverse Rectus Abdominis
Musculocutaneous Flap Model. Ann Plast Surg 2006;56:
320–6.
23- Seify H, Bilkay U, Jones G. Improvement of TRAM flap viability
using human VEGF-induced angiogenesis: A comparative
study of delay techniques. Plast Rec Surg 2003; 112:1032-39.
24- Zhang F, Yang F, Hu EC, et al. Vascular endotelyal growth
factor gene therapy in improvement of skin paddle survival in a
rat TRAM flap model. Rec Microsurg 2005;21:391-6.
25- Cheng JW. Nebivolol: a third generation beta- blocker for
hypertension. Clin Ther 2009;31:447-62.
26- Kalinowski L, Dobrucki L.W, Szczepanska-Konkel M, et al.
Third-generation beta-blockers stimulate nitric oxide release
from endothelial cells through ATP efflux a novel mechanism
for antihypertensive action. Circulation 2003;107:2747–52.
27- Parenti A, Filippi S, Amerini S, et al. Inositol phosphate
metabolism and nitric-oxide synthase activity in endothelial
cells are involved in the vasorelaxant activity of nebivolol. J
Pharmacol Exp Ther 2000;292:698–703.
28- Gosgnach W, Boixel C, Nevo N, et al. Nebivolol induces
calcium-independent signaling in endothelial cells by a
possible beta-adrenergic pathway. J Cardiovasc Pharmacol
2001;38:191–9.
29- Ulisse G, Pasini AF, Stranieri C, et al. Effects of Nebivolol
on Endothelial Gene Expression during Oxidative Stress in
Human Umbilical Vein Endothelial Cells. Mediators Inflamm
2008;2008;367-590.
30- De Groot AA, Mathy MJ, von Zwieten PA, et al. Antioxidant
activity of Nebivolol in the rat aorta. J Cardiovasc Pharmacol
2004;43:148-53.
31- Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits
superoxide formation by NADPH oxidase and endothelial
dysfunction in Angiotensin II–treated rats. Hypertension 2006;
48:677-84.
32- Al-Benna S, Grob M. Primary hypotension: a contraindication
to free tissue transfer? Plast Reconstr Surg 2006;117(7):2509.
33- Gideroglu K, Alagoz S, Uygur F, et al. Effects of nebivolol on
skin flap survival: A randomized experimental study in rats.
Current Therapeutic Research 2008;69:449-58.
34- Kubli S, Feihl F, Waeber B. Beta-blockade with nebivolol
enhances the acetylcholine-induced cutaneous vasodilation.
Clin Pharmacol Ther 2001;69:238-44.

Thank you for copying data from http://www.arastirmax.com